Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease.

摘要: Inflammatory bowel disease (IBD) is the chronic inflammatory disorder of gastrointestinal tract consisting two subtypes: Ulcerative colitis and Crohn's disease. IBD occurs due to infiltration leukocytes in intestinal mucosa derangements barrier function. One most important steps pathogenesis interactions between integrins on surface leukocyte. The α4β7 integrin expressing T-cell an leukocyte involved represents a new drug target for treatment IBD. Vedolizumab humanized monoclonal antibody, which acts against heterodimer blocks interaction with MAdCAM-1. It prevents binding endothelial its extravasation into affected tissue. efficacy safety vedolizumab have been established many clinical studies. has shown promising results various studies where greater percentage patients as compared placebo achieved maintained response, remission, corticosteroid-free remission. be well tolerated slightly higher risk infections, headache, naspharyngitis placebo. This review focuses potential role